Differences in bacteriologic treatment failures in acute otitis externa between ciprofloxacin/dexamethasone and neomycin/polymyxin B/hydrocortisone: Results of a combined analysis

Current Medical Research and Opinion

Volumn 25, Issue 2, 2009, Pages 287-291

  Dohar, Joseph E ^a   Roland, Peter ^b   Wall, G Michael ^c   McLean, Celeste ^c   Stroman, David W ^c  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c ALCON RESEARCH LTD   (United States)

Author keywords

Acute otitis externa; Antibacterial therapy; Ciprofloxacin; Combined analysis; Neomycin; Polymyxin B; Pseudomonas aeruginosa; Staphylococcus aureus

Indexed keywords

CIPROFLOXACIN PLUS DEXAMETHASONE; HYDROCORTISONE; HYDROCORTISONE PLUS NEOMYCIN PLUS POLYMYXIN B; NEOMYCIN; NEOMYCIN PLUS POLYMYXIN B; POLYMYXIN B; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG; CIPROFLOXACIN; DEXAMETHASONE;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM CULTURE; CHI SQUARE TEST; CHILD; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG TREATMENT FAILURE; ERADICATION THERAPY; EXTERNAL OTITIS; HUMAN; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME; ACUTE DISEASE; DRUG COMBINATION; ISOLATION AND PURIFICATION; MICROBIOLOGY; TOPICAL DRUG ADMINISTRATION;

ACUTE DISEASE; ADMINISTRATION, TOPICAL; CIPROFLOXACIN; DEXAMETHASONE; DRUG THERAPY, COMBINATION; HUMANS; HYDROCORTISONE; NEOMYCIN; OTITIS EXTERNA; POLYMYXIN B; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

EID: 64249110196     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990802603072     Document Type: Article

References (19)

1. Beers SL, Abramo TJ. Otitis externa review. Pediatr Emerg Care 2004;20:250-256 (Pubitemid 38496026)
2. Rosenfeld RM, Brown L, Cannon CR, et al. American Academy of Otolaryngology - Head and Neck Surgery Foundation. Clinical practice guideline: acute otitis externa. Otolaryngol Head Neck Surg 2006;134(4 Suppl):S4-23
3. Roland P, Stroman D. Microbiology of acute otitis externa. Laryngoscope 2002;112:1166-1177 (Pubitemid 34747209)
4. Cortisporin [package insert]. Bristol, TN: Monarch Pharmaceuticals, 2003
5. Ciprodex [package insert]. Fort Worth, TX: Alcon Laboratories, Inc., 2004
6. Cipro HC [package insert]. Barcelona, Spain: Alcon Cusi, S.A.; 2006
7. Floxin [package insert]. Montvale, NJ: Daiichi Pharmaceuticals; 2005
8. Cantrell HF, Lombardy EE, Duncanson FP, et al. Declining susceptibility to neomycin and polymyxin B of pathogens recovered in otitis externa clinical trials. South Med J 2004;97:465-471 (Pubitemid 38623777)
9. Sande MA, Mandell GL. Aminoglycosides. In: Gilman AG, Rall TW, Nies AS, Taylor P, eds, Goodman and Gilman's. The Pharmacological Basis of Therapeutics, 8th edn. Oxford: Pergamon Press, 1990: 1112
10. Roland PS, Pien FD, Schultz CC, et al. Ciprodex Otic AOE Study Group. Efficacy and safety of topical ciprofloxacin/dexamethasone versus neomycin/polymyxin B/hydrocortisone for otitis externa. Curr Med Res Opin 2004;20:1175-1183
11. Rahman A, Rizwan S, Waycaster C, et al. Pooled analysis of two clinical trials comparing the clinical outcomes of topical ciprofloxacin/dexamethasone otic suspension and polymyxin B/neomycin/hydrocortisone otic suspension for the treatment of acute otitis externa in adults and children. Clin Ther 2007;29:1950-1956 (Pubitemid 350212800)
12. Ciprodex (Ciprofloxacin & Dexamethasone) Sterile Otic Solution. Application No.: 021537. FDA Medical Review and Microbiology Review accessed November 4, 2008. Available at: http://www.fda.gov/cder/foi/nda/2003/021537- Ciprodex.htm
13. Weber PC, Roland PS, Hannley M, et al. The development of antibiotic resistant organisms with the use of ototopical medications. Otolaryngol Head Neck Surg 2004;130:S89-94 (Pubitemid 38445577)
14. Roland PS, Belcher BP, Bettis R, et al. Cipro HC Study Group. A single topical agent is clinically equivalent to the combination of topical and oral antibiotic treatment for otitis externa. Am J Otolaryngol 2008;29:255-261
15. Barlow DW, Duckert LG, Kreig CS, et al. Ototoxicity of topical otomicrobial agents. Acta Otolaryngol 1995;115:231-235
16. Wright CG, Meyerhoff WL. Ototoxicity of otic drops applied to the middle ear in the chinchilla. Am J Otolaryngol 1984;5:166-176 (Pubitemid 15206874)
17. Brummett RE, Harris RF, Lindgren JA. Detection of ototoxicity from drugs applied topically to the middle ear space. Laryngoscope 1976;86:1177-1187
18. Claes J, Govaerts PJ, van de Heyning PH, et al. Lack of ciprofloxacin ototoxicity after repeated ototopical application. Antimicrob Agents Chemother 1991;35:1014-1016
19. Handzel O, Halperin D. Necrotizing (malignant) external otitis. Am Fam Physician 2003;68:309-312 (Pubitemid 36909395)